WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 27, 2018--
Incyte (NASDAQ:INCY) today announced the appointment of Dashyant Dhanak,
Ph.D. as Executive Vice President and Chief Scientific Officer,
effective December 10, 2018. Dr. Dhanak will succeed Dr. Reid Huber, who
has been at Incyte since 2002 and is leaving the Company to pursue
opportunities in the early-stage life sciences community.
“Reid’s contributions to Incyte have been instrumental in its evolution
from a start-up operation to the world-class discovery engine of today,
and I thank him most sincerely for his commitment and critical thinking
over the last 16 years,” said Hervé Hoppenot, Chief Executive Officer,
Incyte. “Reid’s decision to pursue a different career path has given us
the opportunity to recruit a new leader for our discovery team, and Dash
brings an ideal mix of discovery and development experience into what I
believe is the most innovative and productive group in the industry.”
Dr. Dhanak joins Incyte from Janssen Research & Development, where he
most recently served as Global Head, Discovery Sciences, leading an
organization responsible for supporting and enabling the discovery and
early development of novel therapeutics. Prior to Janssen, Dr. Dhanak
spent 25 years at GlaxoSmithKline.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical
company focused on the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte, please
visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181127005185/en/
Source: Incyte Corporation
+1 302 498 6171
Michael Booth, DPhil
+1 302 498 5914